CEL-SCI Corporation

About CEL-SCI Corporation

CEL-SCI Corporation is a pioneer in cancer immunotherapy. We are a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer, infectious and autoimmune diseases. CEL-SCI believes that boosting a patient's immune system before surgery, radiation and chemotherapy should provide the greatest possible impact on survival since that is the time when the immune system is the strongest. Therefore, in the Phase 3 clinical study CEL-SCI treated patients who were newly diagnosed with head and neck cancer with Multikine immunotherapy right after diagnosis, BEFORE they went on to receive surgery, radiation and/or chemotherapy. This approach is unique since cancer drugs are mostly given after surgery, radiation and chemotherapy have failed. The Phase 3 study is the largest ever in head and neck cancer with 928 patients enrolled. It reached the targeted threshold required to conduct data evaluation and is currently in the statistical analysis phase. Head and neck cancer represents about 6% of all cancers worldwide and an unmet medical need. Multikine has received Orphan Drug designation from the FDA for this indication. CEL-SCI operates its own 73,000 sq. ft. GMP manufacturing facility that produces Multikine and a separate research & development laboratory that supports the manufacturing of Multikine. CEL-SCI has operations in Vienna, Virginia, and near/in Baltimore, Maryland.

Stock Symbol: CVM